Taken together; our study added the wealth knowledge on the pro-tumoral role of FXR in pancreatic cancer and suggested that targeted inhibition of FXR and/or in combination of Sp1 might provide an alternative approach for the management of pancreatic cancer. The gene discussed is NR1H4; the disease is familial pancreatic carcinoma.